Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.56 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | FECH | P22830 | 1/20 | 0.42 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747166 | 0.91 | ERBB2 (0.56) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL31475819 | 0.88 | EGFR (0.43) | EGFRERBB2BRAF | |
| SCHEMBL30050657 | 0.85 | EGFR (0.53) | EGFRERBB2 | |
| SCHEMBL24807827 | 0.85 | EGFR (0.53) | EGFRERBB2 | |
| SCHEMBL23747106 | 0.83 | EGFR (0.50) | EGFRERBB2BRAFNQO2FECH | |
| SCHEMBL31476053 | 0.83 | ERBB2 (0.66) | EGFRERBB2BRAF | |
| SCHEMBL26418909 | 0.83 | ERBB2 (0.66) | EGFRERBB2BRAF | |
| SCHEMBL25432531 | 0.81 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL25999393 | 0.81 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL26428664 | 0.81 | ERBB2 (0.53) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885BRAF 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.